BACK
TO MAIN
PAGE

Respiratory Syncytial Virus (RSV)​

General Information

Respiratory Syncytial Virus (RSV) is a globally prevalent cause of lower respiratory tract infection in all age groups. In infants and young children, the first infection may cause severe bronchiolitis that can sometimes be fatal.

In addition to the paediatric burden of disease, RSV is increasingly being recognised as an important pathogen in older adults, with infection leading to an increase in hospitalisation rates among those aged 65 years and over, and to increased mortality rates among the frail elderly that approach the rates seen with influenza. 

RSV is also a nosocomial threat both to young infants and among immunocompromised and vulnerable individuals.

There are currently no licensed vaccines for RSV.

Show More

Epidemiology

RSV accounts for hospitalisation of 1 in 5 young children < 5 years diagnosed with acute lower respiratory infections and 1 in 6 in adults > 65 years.

RSV is responsible for 24.8 million of acute respiratory infections episodes and 76,600 deaths each year.

RSV:

Vaccines
Pipeline

6
Vaccines in
the pipeline

Technology Platforms

    Live attenuated Virus (1)
    mRNA (3)
    Protein nanoparticles (1)
    Protein subunit (1)

DEVELOPMENT PHASES

    Phase I (1)
    Phase II (2)
    Phase III (2)
    Under review (1)

TRIAL POPULATION

    Paediatric (3)
    Older Adults (3)

Influenza + RSV:

Vaccines
Pipeline

2
Vaccines in
the pipeline

Technology Platforms

    mRNA (1)
    N/A (1)

DEVELOPMENT PHASES

    Phase I (2)

TRIAL POPULATION

    Adults (1)
    Adults + Older Adults (1)

SARS CoV2 + influenza + RSV:

Vaccines
Pipeline

1
Vaccines in
the pipeline

Technology Platforms

    mRNA (1)

DEVELOPMENT PHASES

    Phase I (1)

TRIAL POPULATION

    Adults + Older Adults (1)

SARS CoV2 + RSV:

Vaccines
Pipeline

1
Vaccines in
the pipeline

Technology Platforms

    mRNA (1)

DEVELOPMENT PHASES

    Phase I (1)

TRIAL POPULATION

    N/A (1)

Source: 
https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/respiratory-syncytial-virus-disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320297/
[Accessed: November 2022]

 

Vaccines Europe Pipeline Review

Download our pipeline review